TOMUDEX (ZD1694), A NOVEL AND SPECIFIC THYMIDYLATE SYNTHASE INHIBITOR HAS PROMISING ACTIVITY IN ADVANCED COLORECTAL-CANCER

被引：0
|
作者：
VANCUTSEM, E
CUNNINGHAM, D
ZALCBERG, J
FRANCOIS, E
SCHORNAGEL, JH
ADENIS, A
GREEN, M
STARKHAMMER, H
AZAB, M
机构：
[1] TOMUDEX COLORECTAL CANC STUDY GRP,MACCLESFIELD,ENGLAND
[2] ZENECA PHARMACEUT,MACCLESFIELD,ENGLAND
来源：
GASTROENTEROLOGY | 1995年 / 108卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A548 / A548
页数：1
相关论文
共 40 条
  • [21] Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: Role of dosing schedule and plasma thymidine
    Cao, SS
    McGuire, JJ
    Rustum, YM
    CLINICAL CANCER RESEARCH, 1999, 5 (07) : 1925 - 1934
  • [22] Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; Effect of Tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells
    Aherne, GW
    Hardcastle, A
    Raynaud, F
    Jackman, AL
    BIOCHEMICAL PHARMACOLOGY, 1996, 51 (10) : 1293 - 1301
  • [23] Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (TOMUDEX) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia
    Ek, O
    Reaman, GH
    Crankshaw, DL
    Chelstrom, LM
    Myers, DE
    Uckun, FM
    LEUKEMIA & LYMPHOMA, 1998, 28 (5-6) : 509 - 514
  • [24] 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia (Reprinted from European Journal of Cancer, vol 32A, pg 1945-1954, 1995)
    Cunningham, D
    Zalcberg, JR
    Rath, U
    Olver, I
    VanCutsem, E
    Svensson, C
    Seitz, JF
    Harper, P
    Kerr, D
    PerezManga, G
    Azab, M
    Seymour, L
    Lowery, K
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : R1 - +
  • [25] 'Tomudex' (ZD1694) has a higher response rate, significantly less leucopenia and mucositis and a simpler dosing regimen than 5-fluorouracil (5-FU) and leucovorin (LV) for advanced colorectal cancer (CRC): First results of a phase III study
    Zalcberq, J
    Cunningham, D
    Rath, U
    Olver, I
    Kerr, D
    VanCutsem, E
    Svenson, C
    Seitz, JF
    Harper, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 701 - 701
  • [26] NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer.
    Kazmi, Farasat
    Ciombor, Kristen
    Graham, Janet
    Coveler, Andrew
    Myers, Michelle
    Berlin, Jordan
    Harrison, David
    Blagden, Sarah
    Evans, T. R. Jeffry
    CANCER RESEARCH, 2021, 81 (13)
  • [27] Final results and survival data of a large randomised trial of 'ZD1694' in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5FU+LV).
    VanCutsem, E
    Cunningham, D
    Zalcberg, J
    Rath, U
    Olver, IN
    Kerr, D
    Svensson, C
    Seitz, JF
    Manga, GP
    Harper, P
    Lowery, K
    Azab, M
    GASTROENTEROLOGY, 1996, 110 (04) : A608 - A608
  • [28] A fixed-dose phase I study of ZD9331, a novel non-polyglutamated inhibitor of thymidylate synthase, in patients with refractory cancer
    Bertucci, D
    Ratain, MJ
    Smith, R
    Mani, S
    Vogelzang, NJ
    Schilsky, RL
    Goh, BC
    Smith, M
    Douglass, E
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S286 - S287
  • [29] A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
    A. R. Clamp
    P. Schöffski
    J. W. Valle
    R. H. Wilson
    S. Marreaud
    A.-S. Govaerts
    M. Debois
    D. Lacombe
    C. Twelves
    J. Chick
    G. C. Jayson
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 579 - 585
  • [30] A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
    Clamp, A. R.
    Schoeffski, P.
    Valle, J. W.
    Wilson, R. H.
    Marreaud, S.
    Govaerts, A. -S.
    Debois, M.
    Lacombe, D.
    Twelves, C.
    Chick, J.
    Jayson, G. C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 579 - 585
1234